Keyword: Ian Read

What would a world with no drug rebates look like? Pfizer’s Ian Read is already imagining it.

Even before Pfizer faced Trump's wrath for July price hikes, Novartis decided increasing its own prices wouldn’t be prudent, its CEO said Wednesday.

Pfizer is taking heat from Congress and Wall Street analysts alike for its tepid response to Trump’s demand that it limit price hikes.

Pfizer’s latest overhaul sets biosimilars and hospital drugs alongside innovative products, where they can get brand-level attention.

President Trump convinced one pharma giant to retreat on price increases, and it’s not good news for other price-hiking drugmakers.

Pfizer has three vaccine programs in development—and top executives have high hopes—but two key programs have competitors close behind.

Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.

Investors who've been waiting to see whether serial acquirer Pfizer would strike a megadeal for Bristol-Myers Squibb can cool it, one analyst says.

Pfizer’s board of directors is providing rich incentives to keep CEO Ian Read on board as the company navigates a host of challenges.

Despite competitors' efforts to pick up market share, an analyst figures J&J's Remicade will dominate the market again in 2018.